Celebrating 20 years of Graduate Education
In 2001, the Department of Pharmacology and Toxicology graduate program was established with the mission of providing educational excellence and involvement in cutting edge research in the fields of pharmacology and toxicology. Beginning with just five students, over the past twenty years, our department and graduate program has greatly expanded in student population, faculty, departmental cores, concentrations and programs of study, graduate level certifications, and research areas.
Our department will hold a 20th Anniversary Celebration on Friday, October 15, 2021, in conjunction with our 2021 Earl H. Morris, M.D., Endowed Lectureship key note speaker.
Date: October 15, 2021
Place: Apollo Room, Student Union, Wright State University, 3640 Colonel Glenn Hwy., Dayton, OH 45435 USA
Time: Registration check-in will begin at 9:00 AM in the Skylight Lobby. Festivities will begin at 10:00 AM.
Wright Day to Give
Pharmacology & Toxicology Master’s Program 20th Anniversary Scholarship Fund
In 2001, the Department of Pharmacology & Toxicology in the Boonshoft School of Medicine began its educational mission to provide graduate students with the practical, philosophical, and clinical knowledge necessary to engage in a fulfilling career in the fields of pharmacology and toxicology. Over the past 20 years, our department has now graduated over 280 students whom now hold the degree of Master of Science and are now successfully employed in academia, military positions, and private industry. As a celebration of the milestone of reaching 20 years in practice of graduate education, the department now establishes a scholarship fund to provide financial assistance for students in our master’s program to ensure that the student’s program of study is completed and the Master of Science degree obtained.
The Earl H. Morris, M.D., Endowed Lectureship
The family of Dr. Earl H. Morris established the annual endowed lectureship in 2000. The Department of Pharmacology & Toxicology acts as host for the lecture series. Dr. Mariana Morris, granddaughter of Dr. Earl Morris, was Chair of the Department of Pharmacology & Toxicology from 1997 through 2013. The lectureship was established to honor the altruistic legacy of Dr. Earl Morris, for his outstanding contributions to the Dayton community during more than 50 years of medical practice and for his life-long dedication to the science of medicine.
2021 Morris Keynote Speaker: Houda Alachkar, Pharm.D., PhD.
We are proud to announce that the keynote speaker for this year's Morris Endowed Lectureship is Dr. Houda Alachkar of the University of Southern California, School of Pharmacy.
About Dr. Alachkar
Dr. Alachkar is a 2005 graduate of the Pharmacology & Toxicology Master of Science program. She presented her thesis, “In Vitro Penetration Measurements and Quantitative Structure Permeation Relationships (QSPR) for Pure Chemicals” in the winter of 2005, under the advisement of Dr. Jim McDougal.
Dr. Alachkar continued with her studies at Ohio Northern University, attaining her Doctor of Pharmacy degree in 2011. In 2012, Dr. Alachkar received Doctor of Philosophy of Biomedical Sciences from the Ohio State University, presenting her dissertation, “Novel Biological Insights and Therapeutic Approaches in High-Risk Acute Myeloid Leukemia,” under the advisement Dr. Guido Marcucci. She completed post-doctoral fellowship training in 2015 in clinical pharmacology and pharmacogenomics at the University of Chicago with Dr. Wendy Stock and Dr. Yusuke Nakamura.
Currently, Dr. Alachkar is an assistant professor of Clinical Pharmacy. Her research is focused on treatment and therapies for acute myeloid leukemia.
More information about Dr. Alachkar’s laboratory and research can be found at: https://sites.google.com/view/alachkarlab.
Synopsis of Dr. Alachkar's Lecture
Acute Myeloid Leukemia (AML) is a devastating hematologic malignancy that affects the hematopoietic stem cells. The 5-year overall survival of patients with AML is less than 30%, highlighting the urgent need to identify new therapeutic targets. Our recent efforts to identify novel therapeutic targets in AML focused on mining public genomic and transcriptomic AML data for genes that are differentially overexpressed in AML cells compared with healthy hematopoietic cells. We uncovered new target genes including APOC2 and CD99. My talk will cover important findings related to these two targets. I will present studies conducted in my laboratory demonstrating these genes as viable therapeutic targets in AML both in cellular and in xenograft mouse models. I will also discuss our ongoing work to understand the functions and mechanisms by which these genes contribute to AML. Finally, I will discuss our efforts to develop our discoveries into therapeutic strategies to improve patient's clinical outcome.